top of page
PathoVax LLC, is a start-up company that is based on foundational technology developed at Johns Hopkins University to advance RGVaxTM, the world’s first comprehensive HPV vaccine that aims to target all clinically relevant HPV. It is expected that such additional protection will eventually establish new standards in the $2B HPV market. PathoVax’s collaborative partnerships include well-known institutions such as the U.S. National Cancer Institute to push forward an academic phase 1 study
Board of Directors
Dr Kevin Koh, PhD
Chairman
Dr Robert (‘”Bob”) Becker, PhD MBA is an experienced executive with a proven history in fostering partnerships with product development, cGMP manufacturing, clinical development and regulatory affairs
Cynthia Poa
Director
Mr Jay Nadkarni joins PathoVax with 20+ years of experience in all aspects of new product commercialization and licensing; and has to his credit many successful licensing deals brought to fruition. He has a commendable track record in Innovation Management, Licensing, Business Development, and Technology Transfers for Biopharmaceuticals, Biologics, and Rx / OTC Pharmaceuticals all over the world with emphasis on Tier-1&2 Emerging Markets
Dr Alan Zhu
Director
Dr Joshua Wang
Co-Founder
Anchor 1
Anchor 2
Scientific, Clinical Advisory Board, and Collaborators
Richard Roden, Ph.D
Co-director of Viral Oncology, Johns Hopkins School of medicine
Reinhard Kirnbauer, MD
Director of Viral Oncology,
Medical University Vienna
Warner Huh, M.D
Professor and Division Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham.
John Schiller, Ph.D
NIH Distinguished Investigator (Collaborator)
bottom of page